Benzyl Nicotinate Topical Research: Evidence and Limits
Human topical studies of Benzyl Nicotinate (CAS 94-44-0) have measured local skin perfusion, temperature and redness after controlled experimental application. These studies characterize a response under defined protocols; they do not prove treatment efficacy, general raw-material safety, a suitable concentration or the performance of a commercial finished formulation.
Research question at a glance
| Question | What the reviewed evidence supports | What it does not establish |
|---|---|---|
| Was Benzyl Nicotinate applied topically in human studies? | Yes, in specific experimental preparations and protocols | Suitability of a raw material or every finished formulation |
| What was measured? | Local perfusion/blood-flow, temperature and redness endpoints | Pain relief, arthritis treatment, hair growth or anti-aging efficacy |
| Did response vary? | One study reported variation by anatomical application site | A universal response across sites, people, concentrations or vehicles |
| Does a published response prove safety? | No; endpoint measurement and safety qualification are different questions | A generally safe concentration, daily-use advice or regulatory approval |
Study 1: response kinetics at different anatomical sites
The PubMed record titled “Kinetics of blood flow after topical application of benzyl nicotinate on different anatomic sites” describes an experimental gel applied to human skin. The investigators measured blood flow, temperature and redness over time and reported that the response varied by anatomical site.
This supports a narrow conclusion: site and protocol can affect measured topical-response kinetics. It does not show that Benzyl Nicotinate treats a disease, relieves muscle or joint pain, improves systemic circulation, or performs identically in another vehicle or finished product.
Study 2: comparing perfusion, temperature and redness
A second primary PubMed-indexed topical study compared local blood-flow, temperature and redness endpoints after Benzyl Nicotinate application. These are pharmacodynamic or skin-response measurements, not a commercial specification and not a finished-product efficacy claim.
Endpoint changes must be interpreted with the tested concentration, application area, vehicle, timing, instruments, participant criteria and statistical design. An abstract or a single endpoint cannot be generalized into a broad benefit statement.
Study 3: follicular-pathway experiment
A follicular-pathway study involving six healthy male volunteers used Benzyl Nicotinate and measured perfusion under its experimental conditions. The small, specific study can inform a mechanistic research question about skin pathways. It does not demonstrate hair growth, scalp-health benefits, anti-aging performance or suitability for consumer use.
How to read these studies without overclaiming
| Evidence layer | What to record | Why it limits interpretation |
|---|---|---|
| Chemical identity | CAS 94-44-0, name, purity/impurity profile and analytical confirmation | A name alone does not show that study and purchased material are equivalent |
| Formulation | Vehicle, concentration, co-ingredients, pH and preparation method | Topical delivery and response can depend on the complete formulation |
| Exposure | Amount, area, duration, occlusion, site and repeat schedule | Response at one exposure cannot be extrapolated to another |
| Participants | Number, inclusion criteria, skin site and relevant variability | A small controlled group is not every intended population |
| Endpoint | Instrument, unit, baseline, time course and statistical analysis | Perfusion, temperature and redness are not treatment outcomes |
| Regulatory context | Product category, claims, market, concentration and safety assessment | A published experiment is not a marketing authorization or product approval |
What the reviewed studies do not prove
- Relief of muscle pain, joint pain or arthritis;
- treatment of peripheral circulatory disorders;
- enhanced analgesic or anti-inflammatory efficacy;
- hair growth, scalp health, skin rejuvenation or anti-aging performance;
- systemic oxygen, nutrient or metabolic-waste effects;
- a universally safe concentration, a daily-use schedule or consumer instructions;
- equivalence of an unspecified raw material to a studied formulation;
- regulatory approval or destination-market compliance.
Identity, cosmetic naming and finished-formulation boundary
NIST records Benzyl Nicotinate as CAS 94-44-0 with formula C13H11NON2 and molecular weight 213.2319 g/mol. The European Commission’s ingredient-name glossary includes BENZYL NICOTINATE; an older EU inventory records an antistatic function. These identity and nomenclature records do not establish safety, concentration, grade, therapeutic effect or authorization for an individual product.
Use the Benzyl Nicotinate identity and sourcing guide for the chemical record, procurement fields and regulatory boundary. A finished formulation requires its own composition, exposure, safety, claims and market review.
Questions for a research or formulation RFQ
- What exact study, reference material or target protocol is being followed?
- Which identity, assay, impurity, water and physical-property fields are required?
- Which analytical methods, reference standards and reporting bases apply?
- What formulation, concentration range, process and compatibility work will the buyer perform?
- What product category, destination market, claims and safety assessment apply?
- Which current specification, lot COA, SDS, sample quantity and commercial details are required?
Request current Benzyl Nicotinate information
Open the Benzyl Nicotinate CAS 94-44-0 sourcing page to request the current specification, analytical methods, applicable lot COA, SDS, sample, packaging, MOQ, availability and confirmed lead time.
Courriel info@longchangchemical.com with the study or formulation context, destination market, required tests and limits, quantity, packaging and document requirements.
Frequently asked questions
Do the studies show that Benzyl Nicotinate changes local skin blood flow?
The reviewed experimental studies reported measurable local perfusion responses under their specific topical protocols. The finding should not be generalized beyond the tested conditions.
Do the studies prove that Benzyl Nicotinate treats pain or arthritis?
No. The reviewed endpoints do not establish those treatment outcomes.
Do follicular-pathway results prove hair-growth benefits?
No. A mechanistic perfusion experiment is not evidence of hair growth or scalp-health efficacy.
Can a supplier page determine whether a formulation is safe to use?
No. Safety depends on the complete formulation, concentration, exposure, intended users, claims, market rules and a competent product-specific assessment.
French 
English 
Danish 
German 
Hungarian 
Russian 
Spanish 
Turkish